Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T21:07:12.664Z.
Consensus retrieved: unavailable. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T21:07:12.664Z.
Quote observation: 2026-10-06T20:00:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: cc1b6a3b00dabe5b261e15a58cf0fecaa0dcd4715ed4b38f5f86d2c12a5f1f47
FORWARD PE RATIO
N/A
Cellyan Biotechnology Co., Ltd
Market Cap
$1.13M
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Cellyan Biotechnology Co., Ltd (HKPD) | $1.13M | N/A |
| Propanc Biopharma, Inc. (PPCB)vs › | $1.12M | N/A |
| IM Cannabis Corp. (IMCC)vs › | $1.17M | N/A |
| Clearmind Medicine Inc. (CMND)vs › | $1.08M | N/A |
| Aspire Biopharma Holdings, Inc. (ASBP)vs › | $1.01M | N/A |
| Sunshine Biopharma, Inc. (SBFM)vs › | $946332.00 | N/A |
| Genprex, Inc. (GNPX)vs › | $1.32M | N/A |
| NewcelX Ltd. (NCEL)vs › | $1.33M | N/A |
| Artelo Biosciences, Inc. (ARTL)vs › | $1.34M | N/A |
| GlucoTrack, Inc. (GCTK)vs › | $901902.00 | N/A |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus fiscal-year EPS
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
